Decoupling Dilemmas: China Biotech's Global Balancing Act
East meets West in the lab and the marketplace – how China's evolving biotech sector is navigating US tensions, domestic pressures, and forging a new path forward into 2026.
Zymeworks' Royalty-Driven Pivot: From Canadian Biotech Aspirant to Hybrid Royalty Aggregator
Zymeworks Inc. (NASDAQ/TSX: ZYME) has formally abandoned its ambition to become "Canada's first Big Pharma"
The Weekly Term Sheet (51)
The week of December 15–20, 2025 saw substantial deal flow as companies moved to close transactions before year-end. Total announced deal value exceeded $15 billion across M&A, licensing, royalty acquisitions, and private financings.
Europe's New Biotech Act and Pharma Package: Balancing Innovation and Access
How the EU's December 2025 reforms aim to transform Europe into a biotech powerhouse while keeping medicines affordable—and why success is far from guaranteed
Fund of the week: Baker Brothers Advisors
Baker Brothers Advisors stands as arguably the most successful biotech-focused hedge fund in history, having generated an estimated $8 billion
Company of the week: Amicus Therapeutics
Executive Summary
Amicus Therapeutics (NASDAQ: FOLD) has transformed from a venture-backed rare disease startup into a profitable commercial-stage company with
December 2025 Oncology Conferences: Year-End Data from ASH, SABCS, and ESMO-IO
As 2025 draws to a close, three major oncology conferences delivered substantial clinical trial data that will inform treatment decisions
Global Royalty-Related Deals in Veterinary Pharmaceuticals: A Complete 2023-2025 Market Analysis
The veterinary pharmaceutical sector generated an estimated $650 million to $975 million in annual royalty flows in 2024, representing approximately
Where to List Your Biotech: A Strategic Guide for European Executives in 2025
The question of where to take a biotech company public has never carried higher stakes. In 2025, the transatlantic divide
The Weekly Term Sheet (50)
The week of December 8-13, 2025 delivered extraordinary capital formation across biopharma, with $3.2 billion in follow-on offerings sold
